Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc

24.06
CAD
-0.71
(-2.87%)
0.67EPS
26.93P/E
263.06BMarket Cap
Feb 04Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.92
1.07
1.07
1.17
1.34
1.53
1.61
2.05
2.51
2.89
2.8
2.83
2.98
3.12
Basic EPS, GAAP
0.09
0.12
0.12
0.13
0.14
0.18
0.23
0.41
0.49
0.45
0.39
0.42
0.45
0.47
Free Cash Flow per Basic Share
0.12
0.14
0.16
0.18
0.22
0.24
0.26
0.43
0.43
0.44
0.45
0.48
0.42
0.49
Dividend per Share
0.02
0.01
0.02
0.02
0.02
0.02
0.02
0.02
0.03
0.03
0.03
0.04
0.04
0.04
Book Value per Share
1.17
1.29
1.35
1.38
1.6
1.73
1.88
2.19
2.61
2.84
3.05
3.29
3.58
3.59
Tangible Book Value per Share
-0.19
-0.78
-0.65
-0.88
-1.04
-0.8
-0.64
-0.27
-1.36
-0.95
-0.91
-0.78
-0.79
-1.42
Basic Weighted Avg Shares
14,281
15,783
15,803
15,648
15,656
15,934
15,854
15,696
15,616
15,537
15,299
15,141
14,943
14,834
Sales/Revenue/Turnover
13,090
16,890
16,965
18,274
20,918
24,358
25,542
32,218
39,211
44,915
42,857
42,879
44,557
46,336
Operating Margin (%)
12.89
11.28
14.45
14.49
14.61
15.74
16.37
24.5
26.08
18.94
17.08
18
18.2
18.29
Depreciation Expense
1,000
1,685
1,688
1,758
2,033
2,267
2,277
2,325
2,592
3,381
3,406
3,108
2,780
2,942
Net Income, GAAP
1,273
1,894
1,975
2,022
2,225
2,938
3,696
6,375
7,725
6,950
5,995
6,335
6,704
6,967
Effective Tax Rate (%)
3.06
9.18
- -
- -
8.28
9.93
9.18
11.76
12.54
8.97
4.51
9.34
7.48
7.82
Profit Margin (%)
9.73
11.22
11.64
11.06
10.64
12.06
14.47
19.79
19.7
15.47
13.99
14.77
15.05
15.04
Working Capital
6,755
1,190
1,595
2,155
2,373
4,478
5,696
11,653
6,677
8,219
10,577
8,805
13,518
8,296
LT Debt
9,500
12,352
11,420
15,372
18,873
17,719
17,076
19,107
32,333
28,909
31,308
29,061
35,852
39,181
Total Equity
16,856
20,548
21,350
21,540
25,413
27,586
29,675
34,517
40,977
44,148
46,842
49,672
53,536
52,808
Return on Invested Capital (%)
6.26
7.27
- -
- -
6.42
7.35
8.9
13.3
13.31
9.91
8.19
8.2
8.26
8.3
Return on Capital (%)
6.12
7.46
- -
- -
6.54
7.61
9.17
13.24
12.4
9.84
9.16
9.33
9.2
9.16
Return on Common Equity (%)
7.88
10.13
9.43
9.43
9.48
11.09
12.91
19.87
20.52
16.4
13.22
13.15
13.02
13.5

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3,533
3,090
3,368
LT Borrowings
35,852
40,071
39,181
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14,912
14,729
14,655
Market Capitalization
228,893
188,741
185,357

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
28,707
22,316
23,365
Cash, Cash Equivalents & STI
10,105
3,256
4,064
Accounts Receivable, Net
8,900
9,204
9,451
Inventories
5,425
5,496
5,627
Total Current Liabilities
15,189
14,621
15,069
Payables & Accruals
8,946
8,603
8,785
ST Debt
3,533
3,090
3,368
Deferred Revenue
2,710
2,928
2,918

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.77%
9.28%
7.78%
Free Cash Flow
11.27%
-1.37%
-13.4%
Net Income, GAAP
15.16%
1.78%
5.82%
Sales/Revenue/Turnover
10.53%
7.13%
3.91%
Total Cash Common Dividend
10.36%
13.58%
9.09%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,345
10,541
10,598
11,395
42,879
2025
10,364
10,854
11,122
12,215
44,557
2026
11,005
11,994
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.1
0.11
0.12
0.42
2025
0.1
0.11
0.11
0.13
0.45
2026
0.11
0.12
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
0.01
0.04
2025
0.01
0.01
0.01
0.01
0.04
2026
0.01
0.01
- -
- -
- -

Company Description

CEO
Marc N. Casper
Full Time Employees
125,000
Sector
Health technology
Industry
Medical specialties
Address
168 Third Avenue Waltham MA United States 02451
IPO Date
Aug 27, 1980
Business
Thermo Fisher Scientific Inc. (NYSE: TMO) provides analytical instruments, equipment, software, services, consumables, and reagents for research, analysis, discovery, and diagnostics worldwide. The company offers products including mass spectrometry systems, chromatography instruments, genetic analysis tools, bioprocessing equipment, clinical diagnostics assays, laboratory automation solutions, and electron microscopy technologies; its key brands encompass Thermo Scientific, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon. Headquartered in Waltham, Massachusetts, Thermo Fisher was originally founded in 1902 through the merger of Fisher Scientific and Thermo Electron in 2006, and operates in over 70 countries serving pharmaceutical, biotechnology, academic, government, and healthcare customers across life sciences, analytical technologies, specialty diagnostics, and laboratory products segments. Recently, the company expanded its capabilities through the acquisition of Olink Holding AB in 2024 to bolster proteomics offerings, launched the new Orbitrap Astral mass spectrometer in late 2024 for high-throughput proteomics, and formed strategic partnerships including a multi-year collaboration with AstraZeneca to advance biomarker discovery; in 2025, Thermo Fisher announced expansions in gene editing technologies and sustainable manufacturing initiatives amid ongoing supply chain optimizations.

Company News

  • Thermo Fisher: You Don't Need A Microscope To See The Growth Anymore

  • Thermo Fisher Scientific: 3 Key Takeaways for Long-Term Investors

  • Thermo Fisher Stocks Rise 1.0% as Revenue Growth Beats Estimates

  • Nasdaq Gains 1%; Thermo Fisher Scientific Posts Upbeat Earnings

  • Thermo Fisher Scientific Inc. (TMO) Q3 2026 Earnings Call Transcript

  • TMO Q3 Earnings & Revenues Beat Estimates, Stock Down in Pre-Market

  • Compared to Estimates, Thermo Fisher (TMO) Q3 Earnings: A Look at Key Metrics

  • Thermo Fisher Q3: The Recovery Is Real, And I'm Still Buying

  • Thermo Fisher Scientific Q3 Earnings Call Highlights

  • Thermo Fisher posts higher third-quarter revenue and earnings as margins improve

  • Thermo Fisher Scientific (TMO) Tops Q3 Earnings and Revenue Estimates

  • Thermo Fisher Scientific Reports Third Quarter 2026 Results

  • Why Thermo Fisher (TMO) Could Beat Earnings Estimates Again

  • Top Wall Street Forecasters Revamp Thermo Fisher Scientific Expectations Ahead Of Q3 Earnings

  • Two stocks poised to benefit from rotation out of AI

  • TMO DCF Analysis: Intrinsic Value $421 vs Price $690

  • Banque Pictet & Cie SA Sells 6,618 Shares of Thermo Fisher Scientific Inc. $TMO

  • What Analyst Projections for Key Metrics Reveal About Thermo Fisher (TMO) Q3 Earnings

  • Pfizer, Thermo Fisher Scientific And More: CNBC's ‘Final Trades'

  • Thermo Fisher Scientific (TMO) Reports Next Week: Wall Street Expects Earnings Growth